PDS Biotechnology (NASDAQ:PDSB) Cut to Sell at StockNews.com

StockNews.com cut shares of PDS Biotechnology (NASDAQ:PDSB) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Several other brokerages have also weighed in on PDSB. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $14.25.

PDS Biotechnology Trading Down 1.2 %

NASDAQ PDSB opened at $3.25 on Friday. PDS Biotechnology has a 52 week low of $2.53 and a 52 week high of $6.85. The firm has a 50 day moving average of $3.25 and a two-hundred day moving average of $3.29. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $119.67 million, a PE ratio of -2.66 and a beta of 1.93.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same period in the previous year, the business posted ($0.37) earnings per share. As a group, research analysts expect that PDS Biotechnology will post -1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in PDSB. Tempus Wealth Planning LLC acquired a new stake in PDS Biotechnology during the 2nd quarter worth approximately $55,000. Ground Swell Capital LLC purchased a new position in PDS Biotechnology in the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in PDS Biotechnology during the 2nd quarter worth $115,000. Squarepoint Ops LLC acquired a new stake in shares of PDS Biotechnology in the 2nd quarter worth $120,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of PDS Biotechnology in the second quarter valued at about $146,000. 26.84% of the stock is owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.